Inventor
CLAREMON DAVID A
US147 patents
⚠️ This page may combine multiple inventors who share the name “CLAREMON DAVID A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK & CO INC
31 patentsUS5859041AJan 12, 1999
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC135 citations98
US5717100AFeb 10, 1998
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
MERCK & CO INC116 citations98
US5633251AMay 27, 1997
N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
MERCK & CO INC90 citations96
US5633247AMay 27, 1997
Nitrogen-containing spirocycles
MERCK & CO INC73 citations96
US5595990AJan 21, 1997
Antiarrhythmic benzodiazepines
MERCK & CO INC61 citations96
US5389631AFeb 14, 1995
Fibrinogen receptor antagonists
MERCK & CO INC58 citations96
US5215989AJun 1, 1993
Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
MERCK & CO INC108 citations96
US5206240AApr 27, 1993
Nitrogen-containing spirocycles
MERCK & CO INC77 citations96
US5032598AJul 16, 1991
Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MERCK & CO INC58 citations96
US5030644AJul 9, 1991
Imidazole compounds and their use as transglutaminase inhibitors
MERCK & CO INC72 citations96
US6083949AJul 4, 2000
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
MERCK & CO INC28 citations93
US5658901AAug 19, 1997
2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines
MERCK & CO INC38 citations93
US5098707AMar 24, 1992
Imidazole compounds and their use as transglutaminase inhibitors
MERCK & CO INC29 citations93
US6870055B2Mar 22, 2005
Isoquinolinone potassium channels inhibitors
MERCK & CO INC28 citations92
US6376530B1Apr 23, 2002
Cyclic amidines useful as NMDA NR2B antagonists
MERCK & CO INC22 citations92
US6316474B1Nov 13, 2001
2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
MERCK & CO INC43 citations92
US6303637B1Oct 16, 2001
Heterocyclic potassium channel inhibitors
MERCK & CO INC39 citations92
US6207687B1Mar 27, 2001
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC21 citations92
US6194458B1Feb 27, 2001
Benzamide potassium channel inhibitors
MERCK & CO INC43 citations92
US5726171AMar 10, 1998
N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides
MERCK & CO INC20 citations92
US5426185AJun 20, 1995
Antiarrhythmic benzodiazepines
MERCK & CO INC21 citations92
US5112824AMay 12, 1992
Benzofuran compounds as class III antiarrhythmic agents
MERCK & CO INC25 citations92
US6632836B1Oct 14, 2003
Carbocyclic potassium channel inhibitors
MERCK & CO INC45 citations90
US7592360B2Sep 22, 2009
3-fluoro-piperidines as NMDA/NR2B antagonists
MERCK & CO INC18 citations84
US6403596B1Jun 11, 2002
Substituted pyridones having cytokine inhibitory activity
MERCK & CO INC14 citations84
US7259157B2Aug 21, 2007
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
MERCK & CO INC12 citations83
US7053089B2May 30, 2006
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MERCK & CO INC13 citations82
US6476041B1Nov 5, 2002
1,4 substituted piperidinyl NMDA/NR2B antagonists
MERCK & CO INC16 citations79
US6492516B1Dec 10, 2002
Compounds having cytokine inhibitory activity
MERCK & CO INC9 citations74
US5696111ADec 9, 1997
3-acylaminobenzazepines
MERCK & CO INC13 citations74
US5691332ANov 25, 1997
N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
MERCK & CO INC15 citations74
VITAE PHARMACEUTICALS INC
9 patentsUS9481674B1Nov 1, 2016
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS INC21 citations93
US10047085B2Aug 14, 2018
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS INC14 citations92
US9624217B2Apr 18, 2017
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS INC14 citations92
US10087184B2Oct 2, 2018
Dihydropyrrolopyridine inhibitors of RORγ
VITAE PHARMACEUTICALS INC10 citations84
US9868748B2Jan 16, 2018
Thiazolopyrrolidine inhibitors of ROR- γ
VITAE PHARMACEUTICALS INC13 citations84
US9796710B2Oct 24, 2017
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS INC12 citations84
US9663515B2May 30, 2017
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS INC13 citations84
US7872028B2Jan 18, 2011
Diaminopropanol renin inhibitors
VITAE PHARMACEUTICALS INC14 citations83
US7754737B2Jul 13, 2010
Diaminoalkane aspartic protease inhibitors
VITAE PHARMACEUTICALS INC16 citations83
VITAE PHARMACEUTICALS LLC
5 patentsUS10399976B2Sep 3, 2019
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS LLC11 citations92
US10899758B2Jan 26, 2021
Inhibitors of the menin-MLL interaction
VITAE PHARMACEUTICALS LLC6 citations84
US10807980B2Oct 20, 2020
Dihydropyrrolopyridine inhibitors of ROR-gamma
VITAE PHARMACEUTICALS LLC4 citations84
US10301261B2May 28, 2019
Substituted indoles as modulators of ROR-gamma
VITAE PHARMACEUTICALS LLC6 citations84
US10683302B2Jun 16, 2020
Inhibitors of the menin-MLL interaction
VITAE PHARMACEUTICALS LLC9 citations83
CLAREMON DAVID A
4 patentsUS8242111B2Aug 14, 2012
Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CLAREMON DAVID A36 citations92
US8138178B2Mar 20, 2012
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CLAREMON DAVID A37 citations92
US8440658B2May 14, 2013
Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
CLAREMON DAVID A16 citations84
US8202857B2Jun 19, 2012
1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1
CLAREMON DAVID A21 citations84
CACATIAN SALVACION
1 patentShowing the top 50 of 147 patents by PatentIndex Score.